Can Biological Tests Be Waived? Yes, If Done Correctly

Why Test Waivers Are Often Misunderstood

Waivers are often treated like loopholes or shortcuts. In practice, a good waiver requires more thinking than ordering a test. You need to show why the endpoint is already addressed through device-specific evidence such as material characterization, published literature, prior testing, chemistry data, equivalence, or toxicological risk assessment.

When a Test Waiver Is Appropriate

A waiver is appropriate when the existing evidence is sufficient to address the endpoint without new biological testing. Typical examples include:

• Cytotoxicity waiver: the material has strong biocompatibility history and no new chemical entities or processing changes were introduced.
• Sensitization waiver: the device uses a well-characterized material with no known sensitizers and the finished device state is adequately represented by existing evidence.
• Genotoxicity waiver: chemical characterization and toxicological analysis show no genotoxic compounds above acceptable thresholds.
• Carcinogenicity waiver: for long-contact or implant devices where chemistry and TRA logic show no carcinogenic substances of concern at relevant exposure levels.

What a Valid Waiver Justification Needs

A waiver is not a checkbox. It is a written scientific argument. A strong justification usually contains:

• The endpoint being waived: clearly identify what is not being tested.
• The evidence used: literature, test reports, chemistry data, material specifications, predicate/equivalence logic, or TRA outputs.
• Device relevance: explain why that evidence actually applies to the finished device, its materials, its contact type, and its contact duration.
• A conclusion: state clearly that the endpoint is adequately addressed without additional testing and why.

What Weak Waiver Rationale Looks Like

This is where many submissions fail. Reviewers often push back when the file says "not applicable" or "covered by existing data" without showing the logical bridge from the evidence to the endpoint conclusion.

• Generic language: the rationale is not tied to the actual device or patient-contacting materials.
• No finished-device representation: the evidence is based on raw material data, not the final processed and sterilized device.
• No chemistry bridge: extractables or material characterization exist, but the file does not explain how they support the endpoint conclusion.
• No link to duration or contact type: the waiver ignores one of the core drivers of endpoint applicability.

Why ISO 10993-1:2025 Matters

The 2025 revision strengthens the role of test waivers. It does not just permit them. It makes clear that new biological tests should not be performed when existing evidence is already sufficient. That is good science and better animal-use ethics, but only if the documentation is rigorous.

Where Chemistry and TRA Become Critical

For prolonged-contact and permanent-contact devices, waiver logic often depends heavily on ISO 10993-18 chemical characterization and ISO 10993-17 toxicological risk assessment. If chemistry and toxicology are done well, they can support endpoint conclusions far more effectively than generic waiver wording ever will.

Practical Rule for BEP and BER

The BEP should state the intended waiver strategy and the evidence path that will be used. The BER should present the actual evidence and the final waiver conclusion. When the plan and report align, the waiver reads as part of a controlled scientific process rather than a last-minute omission.